186 related articles for article (PubMed ID: 22139079)
1. The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1.
Muehlich S; Hampl V; Khalid S; Singer S; Frank N; Breuhahn K; Gudermann T; Prywes R
Oncogene; 2012 Aug; 31(35):3913-23. PubMed ID: 22139079
[TBL] [Abstract][Full Text] [Related]
2. Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence.
Hampl V; Martin C; Aigner A; Hoebel S; Singer S; Frank N; Sarikas A; Ebert O; Prywes R; Gudermann T; Muehlich S
EMBO Mol Med; 2013 Sep; 5(9):1367-82. PubMed ID: 23853104
[TBL] [Abstract][Full Text] [Related]
3. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
4. Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.
Zhu W; Ma L; Yang B; Zheng Z; Chai R; Liu T; Liu Z; Song T; Li F; Li G
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):589-97. PubMed ID: 26935193
[TBL] [Abstract][Full Text] [Related]
5. SAP domain-dependent Mkl1 signaling stimulates proliferation and cell migration by induction of a distinct gene set indicative of poor prognosis in breast cancer patients.
Gurbuz I; Ferralli J; Roloff T; Chiquet-Ehrismann R; Asparuhova MB
Mol Cancer; 2014 Feb; 13():22. PubMed ID: 24495796
[TBL] [Abstract][Full Text] [Related]
6. H2O2 inhibits proliferation and mediates suppression of migration via DLC1/RhoA signaling in cancer cells.
Ma L; Zhu WZ; Liu TT; Fu HL; Liu ZJ; Yang BW; Song TY; Li GR
Asian Pac J Cancer Prev; 2015; 16(4):1637-42. PubMed ID: 25743845
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
Wu HT; Xie CR; Lv J; Qi HQ; Wang F; Zhang S; Fang QL; Wang FQ; Lu YY; Yin ZY
Lab Invest; 2018 Aug; 98(8):1014-1024. PubMed ID: 29785050
[TBL] [Abstract][Full Text] [Related]
8. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
9. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
10. Induction of megakaryocyte differentiation drives nuclear accumulation and transcriptional function of MKL1 via actin polymerization and RhoA activation.
Smith EC; Teixeira AM; Chen RC; Wang L; Gao Y; Hahn KL; Krause DS
Blood; 2013 Feb; 121(7):1094-101. PubMed ID: 23243284
[TBL] [Abstract][Full Text] [Related]
11. The intracellular stability of DLC1 is regulated by the 26S proteasome in human hepatocellular carcinoma cell line Hep3B.
Luo HW; Luo QP; Yuan Y; Zhu XY; Huang SF; Peng Z; Li CL; Huang ZG; Feng WL
Biochem Biophys Res Commun; 2011 Jan; 404(1):279-83. PubMed ID: 21130076
[TBL] [Abstract][Full Text] [Related]
12. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.
Xue W; Krasnitz A; Lucito R; Sordella R; Vanaelst L; Cordon-Cardo C; Singer S; Kuehnel F; Wigler M; Powers S; Zender L; Lowe SW
Genes Dev; 2008 Jun; 22(11):1439-44. PubMed ID: 18519636
[TBL] [Abstract][Full Text] [Related]
13. DLC1: a significant GAP in the cancer genome.
Lahoz A; Hall A
Genes Dev; 2008 Jul; 22(13):1724-30. PubMed ID: 18593873
[TBL] [Abstract][Full Text] [Related]
14. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.
Chan LK; Ko FC; Sze KM; Ng IO; Yam JW
PLoS One; 2011; 6(9):e25547. PubMed ID: 21966542
[TBL] [Abstract][Full Text] [Related]
15. Pro-senescence therapy for hepatocellular carcinoma.
Muehlich S; Gudermann T
Aging (Albany NY); 2013 Sep; 5(9):639-40. PubMed ID: 24057649
[No Abstract] [Full Text] [Related]
16. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.
Chung GE; Yoon JH; Lee JH; Kim HY; Myung SJ; Yu SJ; Lee SH; Lee SM; Kim YJ; Lee HS
Oncol Rep; 2011 Jun; 25(6):1739-46. PubMed ID: 21455586
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
19. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes.
Cen B; Selvaraj A; Burgess RC; Hitzler JK; Ma Z; Morris SW; Prywes R
Mol Cell Biol; 2003 Sep; 23(18):6597-608. PubMed ID: 12944485
[TBL] [Abstract][Full Text] [Related]
20. DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis.
Ritchey L; Ha T; Otsuka A; Kabashima K; Wang D; Wang Y; Lowy DR; Tosato G
Oncogene; 2019 Nov; 38(45):7046-7059. PubMed ID: 31409902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
